Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis
Diabetes Research and Clinical Practice | Jan 12, 2018
El Masri D, et al. - This systematic review was performed to investigate the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on HbA1c, body weight, and total daily insulin dose, as well as their safety profile in patients with type 1 diabetes. Findings supported the development of SGLT2 inhibitors in combination with insulin as a treatment option for patients with type 1 diabetes.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
